This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Pediatrics  • Adolescent Medicine  • Psychiatry  • Quality of Care  • Patient Safety/ Medical Error  • Drug Therapy  • Adverse Effects  • Pediatric Dosing  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2009;302(8):833-834.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Despite safety concerns, a US Food and Drug Administration (FDA) advisory panel recommended in June that the agency approve 3 atypical antipsychotic drugs for the treatment of children and adolescents with bipolar disorder or schizophrenia. The drugs are associated with substantial weight gain and metabolic problems.

An expert panel advised the US Food and Drug Administration to approve quetiapine, ziprasidone, and olanzapine for use in some children with bipolar disorder or schizophrenia. (Credit: Molecule Data Source: DrugBank Accession Nos. DB01124, DB00334, DB00246)

Two atypical antipsychotic drugs, risperidone and aripiprazole, are currently approved for the treatment of these conditions in pediatric patients. But the FDA asked its advisors to consider whether there is sufficient evidence to support approval of 3 similar drugs for use in younger patients. These drugs—quetiapine, ziprasidone, and olanzapine—are currently approved for treating schizophrenia or bipolar disorder in adults and are used widely off label . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?